Tumor organoids are superior 3D in vitro models with enhanced predictivity for more clinically relevant early drug development.
Tumor organoid screens provide more translatable in vitro data to improve success rates of your new anticancer agents.
You can now achieve rapid results through our preset tumor organoid screening packages, with organoids developed using exclusive HUB protocols.
To rapidly identify your lead agent from a library of 10+ compounds
To quantitatively evaluate the efficacy and potency of your agent/s across models representing a heterogenous patient population
To identify optimal dosing for your combination strategies
To rapidly identify your lead agent from a library of 10+ compounds
To quantitatively evaluate the efficacy and potency of your agent/s across models representing a heterogenous patient population
To identify optimal dosing for your combination strategies
To rapidly identify your lead agent from a library of 10+ compounds
To quantitatively evaluate the efficacy and potency of your agent/s across models representing a heterogenous patient population
To identify optimal dosing for your combination strategies
To rapidly identify your lead agent from a library of 10+ compounds
To quantitatively evaluate the efficacy and potency of your agent/s across models representing a heterogenous patient population
To identify optimal dosing for your combination strategies
To rapidly identify your lead agent from a library of 10+ compounds
To quantitatively evaluate the efficacy and potency of your agent/s across models representing a heterogenous patient population
Your privacy is important to us.
We'll never share your information.
© 2025 Crown Bioscience. All Rights Reserved.
Privacy Policy | Imprint | Terms of Service | Privacy Preferences
© 2025 Crown Bioscience. All Rights Reserved. Privacy Policy
2023-09-06
2022-04-11
landing_page
PDX/Databases